TY - JOUR
T1 - A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses
AU - Malnati, Mauro S.
AU - Heltai, Silvia
AU - Cosma, Antonio
AU - Reitmeir, Peter
AU - Allgayer, Simone
AU - Glashoff, Richard H.
AU - Liebrich, Walter
AU - Vardas, Eftyhia
AU - Imami, Nesrina
AU - Westrop, Samantha
AU - Nozza, Silvia
AU - Tambussi, Giuseppe
AU - Buttò, Stefano
AU - Fanales-Belasio, Emanuele
AU - Ensoli, Barbara
AU - Ensoli, Fabrizio
AU - Tripiciano, Antonella
AU - Fortis, Claudio
AU - Lusso, Paolo
AU - Poli, Guido
AU - Erfle, Volker
AU - Holmes, Harvey
N1 - Funding Information:
This work was supported by the AIDS Vaccine Integrated Project (AVIP) ( EU contract LSHP-CT-2004-503487 ) and by grants of the VI Italian National AIDS Research Program of the Istituto Superiore di Sanità, Rome, Italy (to MSMS) including the “ELVIS” concerted action on LTNP (to FE and GP). All the peptide pools were provided by the Centre for AIDS Reagents NIBSC, UK through the EU Programme EVA.
PY - 2012/1/31
Y1 - 2012/1/31
N2 - Delineation of the immune correlates of protection in natural infection or after vaccination is a mandatory step for vaccine development. Although the most recent techniques allow a sensitive and specific detection of the cellular immune response, a consensus on the best strategy to assess their magnitude and breadth is yet to be reached. Within the AIDS Vaccine Integrated Project (AVIP http://www.avip-eu.org) we developed an antigen scanning strategy combining the empirical-based approach of overlapping peptides with a vast array of database information. This new system, termed Variable Overlapping Peptide Scanning Design (VOPSD), was used for preparing two peptide sets encompassing the candidate HIV-1 vaccine antigens Tat and Nef. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets in a trial involving six laboratories of the AVIP consortium. Cross-reactive background responses were measured in 80 HIV seronegative donors (HIV-), while sensitivity and magnitude of Tat and Nef-specific T-cell responses were assessed on 90 HIV+ individuals. In HIV-, VOPSD peptides generated background responses comparable with those of the standard sets. In HIV-1+ individuals the VOPSD pools showed a higher sensitivity in detecting individual responses (Tat VOPSD vs. Tat 15mers or 20mers: p ≤ 0.01) as well as in generating stronger responses (Nef VOPSD vs. Nef 20mers: p < 0.001) than standard sets, enhancing both CD4 and CD8 T-cell responses. Moreover, this peptide design allowed a marked reduction of the peptides number, representing a powerful tool for investigating novel HIV-1 candidate vaccine antigens in cohorts of HIV-seronegative and seropositive individuals.
AB - Delineation of the immune correlates of protection in natural infection or after vaccination is a mandatory step for vaccine development. Although the most recent techniques allow a sensitive and specific detection of the cellular immune response, a consensus on the best strategy to assess their magnitude and breadth is yet to be reached. Within the AIDS Vaccine Integrated Project (AVIP http://www.avip-eu.org) we developed an antigen scanning strategy combining the empirical-based approach of overlapping peptides with a vast array of database information. This new system, termed Variable Overlapping Peptide Scanning Design (VOPSD), was used for preparing two peptide sets encompassing the candidate HIV-1 vaccine antigens Tat and Nef. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets in a trial involving six laboratories of the AVIP consortium. Cross-reactive background responses were measured in 80 HIV seronegative donors (HIV-), while sensitivity and magnitude of Tat and Nef-specific T-cell responses were assessed on 90 HIV+ individuals. In HIV-, VOPSD peptides generated background responses comparable with those of the standard sets. In HIV-1+ individuals the VOPSD pools showed a higher sensitivity in detecting individual responses (Tat VOPSD vs. Tat 15mers or 20mers: p ≤ 0.01) as well as in generating stronger responses (Nef VOPSD vs. Nef 20mers: p < 0.001) than standard sets, enhancing both CD4 and CD8 T-cell responses. Moreover, this peptide design allowed a marked reduction of the peptides number, representing a powerful tool for investigating novel HIV-1 candidate vaccine antigens in cohorts of HIV-seronegative and seropositive individuals.
KW - ELISpot
KW - HIV-1
KW - Nef
KW - Peptide
KW - Tat
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84855346712&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2011.09.005
DO - 10.1016/j.jim.2011.09.005
M3 - Article
C2 - 21963950
AN - SCOPUS:84855346712
SN - 0022-1759
VL - 375
SP - 46
EP - 56
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
IS - 1-2
ER -